Results 141 to 150 of about 78,600 (311)

Pennsylvania state-wide hemophilia program: summary of immediate reactions with the use of factor VIII and factor IX concentrate [PDF]

, 1979
David Prager, I. Djerassi, M. Elaine Eyster, FM Gill, NK Kajani, JH Lewis, Charles J. Lusch, Samuel L. Rice, Shapiro Ss   +8 more
openalex   +1 more source

Quality of Life and Treatment Satisfaction in People With Haemophilia on Fitusiran Prophylaxis: Evidence From a Subset of ATLAS‐OLE Trial Participants Mainly From India

Haemophilia, EarlyView.
Alok Srivastava, Savita Rangarajan, Cecil Ross, Shariq Ali, Shauna Andersson, Laurel A. Menapace, Marja Puurunen, Marion Afonso   +7 more
wiley   +1 more source

Standardization of Terminology, Definitions, and Outcome Criteria for Bleeding in Hereditary Hemorrhagic Telangiectasia: International Consensus Report

American Journal of Hematology, Volume 100, Issue 10, Page 1813-1827, October 2025.
ABSTRACT Hereditary hemorrhagic telangiectasia (HHT, Osler‐Weber‐Rendu disease) is the second most common inherited bleeding disorder worldwide, affecting approximately 1 in 5000 people. Development of disease‐modifying and efficacious hemostatic agents to treat HHT has finally begun after decades without such medical therapies.
Hanny Al‐Samkari, Raj S. Kasthuri, Hans‐Jurgen Mager, Jenny Y. Zhou, Marcelo M. Serra, Bethany T. Samuelson‐Bannow, Layla N. Van Doren, Jay F. Piccirillo, Marianne S. Clancy, Keith R. McCrae, Sonia M. Thomas, Antoni Riera‐Mestre, Allyson M. Pishko, Sarah Sewaralthahab, James R. Gossage, Vivek N. Iyer, Cedric Hermans, Adrienne Hammill, Ingrid Winship, Meir Mei‐Zahav, Annette von Drygalski, Scott Olitsky, Marie E. Faughnan   +22 more
wiley   +1 more source

Isolation and Properties of the Abnormal Factor IX Molecule of Hemophilia BM [PDF]

, 1977
Bjarne Østerud, K K Lavine, Carol K. Kasper, Samuel I. Rapaport   +3 more
openalex   +1 more source

Collected Experience of the Pennsylvania Hemophilia Program [PDF]

, 1977
S.S. Shapiro, M.E. Eyster, J. Lewis
openalex   +1 more source

Correction to “Immune Tolerance Induction With a Recombinant Factor VIII Fc in Haemophilia A: Data From a Chart Review Study”

European Journal of Haematology, EarlyView.
wiley   +1 more source

Technical Note and Short Review: A Challenging Case of a Premature Newborn Presenting With ICH, IVH, Ventriculitis, and Hydrocephalus

Clinical Case Reports, Volume 13, Issue 10, October 2025.
ABSTRACT Premature infants are at a heightened risk of intracerebral or intraventricular hemorrhages (IVH), which often lead to posthaemorrhagic hydrocephalus and necessitate the placement of a ventriculoperitoneal (VP) shunt. Here, we present a case involving suspected ICH, which led to multiloculated hydrocephalus, recurrent ventriculitis, and ...
Hannes Egermann, Christian Knorr, Basheer Al‐Shameri, Adolf Müller, Markus Denzinger, Stephan Lackermair   +5 more
wiley   +1 more source

Defibrination Syndrome Developed after Replacement Therapy with PPSB in a Case of Hemophilia B. [PDF]

, 1977
Mutsuyoshi Kazama, H Iwakura, Masaru Nakajima, M. Abe, Tetsuya Abe   +4 more
openalex   +1 more source

A Story Worth Telling: The Evolution of Haemophilia Care in Canada

Haemophilia, EarlyView.
Kelsey Uminski, Adrienne Lee
wiley   +1 more source

Relationship between Dose, Factor IX Activity Levels and Bleeding Probability for rIX‐FP Prophylaxis in Hemophilia B: A Repeated Time‐to‐Event Analysis

Clinical Pharmacology &Therapeutics, Volume 118, Issue 4, Page 831-840, October 2025.
In hemophilia B, pharmacokinetic (PK)‐guided dosing of extended half‐life factor IX (EHL‐FIX) concentrates can secure targeted FIX exposure. Target FIX activity levels in plasma should be individually set primarily taking bleeding tendency into account, alongside the presence of target joints, physical activity, and preferred dosing schedules. In other
Sjoerd F. Koopman, Marjon H. Cnossen, Ron A.A. Mathot, on behalf of the OPTI‐CLOT study group and SYMPHONY consortium, S. H. Reitsma   +4 more
wiley   +1 more source